The approvals are based on a Phase 3 study that showed the Keytruda-Welireg combo cut the risk of the cancer coming back, spreading or death by 28% compared with Keytruda plus pla ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant pembrolizumab appeared associated with a significant and clinically meaningful improvement in DFS vs.

The FDA has approved belzutifan (Welireg, Merck) in combination with pembrolizumab (Keytruda, Merck) or the subcutaneous ...

In an earlier study on kidney donors we found that nephrectomy shifts the action of Ang II from the afferent towards the efferent arteriole, 4 increasing efferent resistance and filtration pressure.

Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses From January 1989 to July 2005, we identified ...

An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for innovative imaging ...

Kidney removal surgery, a nephrectomy, can cause pain. While most discomfort fades in weeks, some patients experience chronic pain. Understanding different pain types like flank, back, and nerve pain ...

For years, the standard protocol when performing a partial nephrectomy has been to leave a drain for monitoring postoperative complications, such as urinary fistulae and hemorrhage. Contemporary ...

A patient self-administers a finger prick blood test. Patients undergoing nephrectomy for RCC have a higher risk of death if they have diabetes, a new study suggests. Patients undergoing nephrectomy ...

When current literature is reviewed, it is found that factors that in uence renal function after partial nephrectomy, are multifactorial. Those are divided into pre-surgical factors, such as ...

Prediction of response to sunitinib in patients with advanced renal cell carcinoma (RCC) using mass spectrometry-based (phospho) proteomics. This is an ASCO Meeting Abstract from the 2021 ASCO Annual ...

Nephrectomy after HIF-2α antagonist therapy is feasible and safe. Renal surgery following or during exposure to a HIF-2α antagonist appears safe and feasible, with perioperative transfusion rates and ...